SM03 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	3

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04312815 (ClinicalTrials.gov)	December 28, 2017	16/3/2020	A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX	A Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severely Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis(RA)	Drug: SM03;Drug: Placebo;Drug: MTX	SinoMab Pty Ltd	NULL	Recruiting	18 Years	70 Years	All	510	Phase 3	China
2	NCT04192617 (ClinicalTrials.gov)	December 31, 2014	5/12/2019	A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate	A Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase II Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severe Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: SM03;Drug: Placebo;Drug: Methotrexate	SinoMab Pty Ltd	NULL	Completed	18 Years	75 Years	All	156	Phase 2	China
3	NCT04704492 (ClinicalTrials.gov)	August 14, 2012	6/1/2021	A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis	An Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Preliminary Clinical Activity and Safety of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Biological: SM03	SinoMab Pty Ltd	NULL	Completed	18 Years	65 Years	All	8	Phase 1	China